Ku­ra's AML drug pass­es key study in ad­vanced pa­tients, plans next steps with FDA and new­ly di­ag­nosed stud­ies

The race is on be­tween Ku­ra On­col­o­gy and Syn­dax Phar­ma­ceu­ti­cals.

On Wednes­day, Ku­ra and its part­ner Ky­owa Kirin an­nounced that their tar­get­ed treat­ment ziftomenib suc­ceed­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER